Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy DOI Creative Commons

Christina Bruß,

Veruschka Albert,

Stephan Seitz

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Апрель 29, 2024

Pre-operative radiation therapy is not currently integrated into the treatment protocols for breast cancer. However, transforming immunological “cold” cancers by neoadjuvant irradiation their “hot” variants supposed to elicit an endogenous tumor immune defense and, thus, enhance immunotherapy efficiency. We investigated cellular and effects of sub-lethal, ER pos., HER2 triple-negative cancer subtypes in-vitro in-vivo in humanized mice (HTM). This mouse model characterized a human-like system therefore facilitates detailed analysis mechanisms efficiency neoadjuvant, irradiation-induced “in-situ vaccination”, especially context concurrently applied checkpoint therapy. Similar clinical appearances, we observed gradually increased immunogenicity from luminal over HER2-pos. triple negative subtype HTM indicated increasing cell infiltration tissue. Anti-PD-L1 divided groups responder non-responder, while HTMs were basically irresponsive. Irradiation alone was effective subtype-specific supportive overcoming irresponsiveness single anti-PD-L1 treatment. The success correlated with significantly T proportion PD-1 expression spleen. In all combination proved most diminishing growth, enhancing response, converted non-responder during HTM, reinforced –specific manner. According “bench bedside” principle, this study offers vital foundation translating use

Язык: Английский

Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? DOI Creative Commons
Lin Ma,

Liufu Deng,

Jianfeng Peng

и другие.

Cancer Biology and Medicine, Год журнала: 2024, Номер 20(12), С. 1035 - 1046

Опубликована: Фев. 5, 2024

Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy stage IV NSCLC has incited interest similar approaches for LA-NSCLC. Several recent investigations involving synergistic potential combined radiotherapy (iRT) have generated encouraging results. This review discusses existing studies and prospective directions chemotherapy-free iRT strategies Although initial findings shown promising efficacy, we must consider methodologic limitations current myriad challenges that accompany implementation iRT. These include determining optimal dose fractionation, precise target volume delineation, identification additional suitable patient cohorts. Furthermore, feasibility as a novel treatment modality select LA-NSCLC is contingent upon validation through randomized phase III trials.

Язык: Английский

Процитировано

4
Case Report: Intensity-modulated radiotherapy combined with immunotherapy for intramedullary spinal cord metastases of lung adenocarcinoma DOI Creative Commons
Yingying He,

Fei Xie,

Tianli He

и другие.

Frontiers in Oncology, Год журнала: 2025, Номер 15

Опубликована: Март 10, 2025

Intramedullary spinal cord metastases (ISCMs) are rare in clinical practice and their presentation is usually an unfavorable sign with a median overall survival (mOS) of 3-4 months after diagnosis. Due to rarity, heterogeneity rapid progression, clinicians have few satisfactory guidelines or optimal management for ISCMs. Herein, we share experience intensity-modulated radiotherapy (IMRT) combined immunotherapy (IO) ISCMs from lung adenocarcinoma (LUAD) that achieved relatively high quality life 10 months, which has not been previously reported.

Язык: Английский

Процитировано

0
The role of chemoradiotherapy and immunotherapy in stage III NSCLC DOI Creative Commons

Zsuzsanna Orosz,

Árṕad Kov́acs

Pathology & Oncology Research, Год журнала: 2024, Номер 30

Опубликована: Апрель 19, 2024

Locally advanced non-small lung cancer encompasses a diverse range of tumors. In the last few years, treatment stage III unresectable has evolved significantly. The PACIFIC trial opened new therapeutic era in locally NSCLC, establishing durvalumab consolidation therapy as standard care worldwide. A careful evaluation this type and discussion management these patients within multidisciplinary team represents crucial step defining best strategy for each patient. For definitive concurrent chemoradiotherapy (CCRT) was historically recommended with 5-year survival rate ranging from 20% to 30%. study conducted 2017 compared use maintenance anti-PD-L1 monoclonal antibody placebo NSCLC who had not experienced disease progression. prospective, randomized, phase III. administration medication cell (NSCLC) demonstrated notable improvement overall survival. Multiple clinical trials are currently exploring various immune checkpoint inhibition regimens enhance efficacy cancer. Our goal is offer an up-to-date summary planned options, focusing on significant obstacles prospects post-PACIFIC era.

Язык: Английский

Процитировано

3
Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy DOI Creative Commons

Christina Bruß,

Veruschka Albert,

Stephan Seitz

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Апрель 29, 2024

Pre-operative radiation therapy is not currently integrated into the treatment protocols for breast cancer. However, transforming immunological “cold” cancers by neoadjuvant irradiation their “hot” variants supposed to elicit an endogenous tumor immune defense and, thus, enhance immunotherapy efficiency. We investigated cellular and effects of sub-lethal, ER pos., HER2 triple-negative cancer subtypes in-vitro in-vivo in humanized mice (HTM). This mouse model characterized a human-like system therefore facilitates detailed analysis mechanisms efficiency neoadjuvant, irradiation-induced “in-situ vaccination”, especially context concurrently applied checkpoint therapy. Similar clinical appearances, we observed gradually increased immunogenicity from luminal over HER2-pos. triple negative subtype HTM indicated increasing cell infiltration tissue. Anti-PD-L1 divided groups responder non-responder, while HTMs were basically irresponsive. Irradiation alone was effective subtype-specific supportive overcoming irresponsiveness single anti-PD-L1 treatment. The success correlated with significantly T proportion PD-1 expression spleen. In all combination proved most diminishing growth, enhancing response, converted non-responder during HTM, reinforced –specific manner. According “bench bedside” principle, this study offers vital foundation translating use

Язык: Английский

Процитировано

2